Author:
Aslan Erdogan,Bagis Tayfun,Kilicdag Esra Bulgan,Tarim Ebru,Erkanli Serkan,Kuscu Esra
Subject
Obstetrics and Gynecology,General Biochemistry, Genetics and Molecular Biology
Reference18 articles.
1. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial;Writing Group for the Women's Health Initiative Investigators;JAMA,2002
2. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women;Hulley;JAMA,1998
3. Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen–Progestin Replacement Study (HERS);Simon;Circulation,2001
4. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy;Skouby;Maturitas,2005
5. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER)s publication. Guidance for industry: estrogen and estrogen/progestin drug products to treat vasomotor symptoms, and vulvar vaginal atrophy symptoms: recommendations for clinical evaluation, 2003. Available at http://www.fda.gov/cder/guidance/5412dft.pdf (accessed on April 9, 2003).
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献